To PLEX or Not to PLEX for Amiodarone-Induced Thyrotoxicosis

Tania Ahuja; Olivia Nuti; Cameron Kemal; Darren Kang; Eugene Yuriditsky; James M Horowitz; Raymond A Pashun

doi:10.1155/2023/1563732

To PLEX or Not to PLEX for Amiodarone-Induced Thyrotoxicosis

Case Rep Cardiol. 2023 Nov 20:2023:1563732. doi: 10.1155/2023/1563732. eCollection 2023.

Authors

Tania Ahuja^{1

2}, Olivia Nuti², Cameron Kemal¹, Darren Kang³, Eugene Yuriditsky¹, James M Horowitz¹, Raymond A Pashun¹

Affiliations

¹ Department of Medicine, The Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, USA.
² Department of Pharmacy, New York University Langone Health, New York, New York 10016, USA.
³ Department of Advanced Practice Practitioners, New York University Langone Health, New York, New York 10016, USA.

Abstract

Amiodarone-induced thyrotoxicosis (AIT) carries significant cardiovascular morbidity. There are two types of AIT with treatment including antithyroid medications and corticosteroids and treatment of ventricular arrhythmias. Therapeutic plasma exchange (TPE) also known as "PLEX" may help remove thyroid hormones and amiodarone. We report a case of PLEX in an attempt to treat cardiogenic shock secondary to AIT. This case highlights the robust rapidly deleterious demise of AIT, specifically in patients with decompensated heart failure. The decision to PLEX or not to PLEX for AIT should be individualized, prior to definitive therapy.

Publication types

Case Reports